Press release
Nonalcoholic Steatohepatitis (NASH) Market valued at around USD 4.5 billion in 2024 and is projected to reach about USD 22.5 billion by 2034
Nonalcoholic Steatohepatitis (NASH) Market
The Nonalcoholic Steatohepatitis (NASH) Market is growing steadily due to rising obesity, diabetes prevalence, and progress in late-stage drug development. The market was valued at around USD 4.5 billion in 2024 and is projected to reach about USD 22.5 billion by 2034, expanding at a CAGR of nearly 17%. Growing diagnosis rates and strong R&D pipelines from leading pharmaceutical companies are major growth contributors.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71159
Key Market Drivers
• Increasing global incidence of obesity, metabolic syndrome, and type 2 diabetes, leading to higher NASH prevalence.
• Strong pharmaceutical R&D investment with multiple late-stage clinical trials.
• Rising adoption of non-invasive diagnostic tools such as imaging biomarkers and blood-based tests.
• Growing awareness about fatty liver diseases and the risks of cirrhosis and liver failure.
Challenges
• Lack of approved, highly effective monotherapies for advanced NASH.
• Difficulty in accurate and early diagnosis due to asymptomatic progression.
• High drug development costs and clinical trial complexities.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71159/nonalcoholic-steatohepatitis-market
Market Segmentation
By Drug Type
• Vitamin E
• Pioglitazone
• Obeticholic acid
• Elafibranor
• Saroglitazar
• Others in pipeline
By Route of Administration
• Oral
• Injectable
By Distribution Channel
• Hospital pharmacies
• Retail pharmacies
• Online pharmacies
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71159
Regional Insights
• North America leads due to high obesity rates, strong clinical trials, and major pharmaceutical players.
• Europe shows significant adoption of diagnostic technologies and rising disease awareness.
• Asia-Pacific is an emerging high-growth region with increasing metabolic disorder cases and improving healthcare access.
Key Companies
Gilead Sciences, Intercept Pharmaceuticals, Genfit, Novo Nordisk, Bristol Myers Squibb, AstraZeneca, Eli Lilly, Pfizer, Galmed Pharmaceuticals, Zydus.
Future Outlook
The market is expected to accelerate as multiple late-stage pipeline drugs move toward commercialization, alongside increasing physician awareness and the adoption of non-invasive diagnostics. Combination therapies and personalized treatment approaches will shape the next decade.
This report is also available in the following languages : Japanese (非アルコール性脂肪肝炎市場), Korean (비알코올성 지방간염 시장), Chinese (非酒精性脂肪性肝炎市场), French (Marché de la stéatohépatite non alcoolique), German (Markt für nichtalkoholische Steatohepatitis), and Italian (Mercato della steatoepatite non alcolica), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71159
Our More Reports:
Voice Prosthesis Devices Market
https://exactitudeconsultancy.com/reports/70774/voice-prosthesis-devices-market
Hearing Aid Devices Market
https://exactitudeconsultancy.com/reports/70776/hearing-aid-devices-market
Powered Surgical Instrument Market
https://exactitudeconsultancy.com/reports/70778/powered-surgical-instrument-market
Autosomal Dominant Polycystic Kidney Disease Market
https://exactitudeconsultancy.com/reports/70780/autosomal-dominant-polycystic-kidney-disease-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis (NASH) Market valued at around USD 4.5 billion in 2024 and is projected to reach about USD 22.5 billion by 2034 here
News-ID: 4311784 • Views: …
More Releases from Exactitude Consultancy
Continuous Renal Replacement Therapy (CRRT) Machines Market is projected to reac …
The global Continuous Renal Replacement Therapy (CRRT) Machines Market was valued at USD 2.98 billion in 2024 and is projected to reach USD 5.67 billion by 2034, expanding at a CAGR of 6.9% from 2025 to 2034. This growth is driven by increasing incidence of acute kidney injury (AKI) in critically ill patients, rising intensive care unit (ICU) admissions, growing adoption of advanced renal support devices, and expanding healthcare infrastructure…
Inguinal Hernia Market Growing at a CAGR of about 4.1%
Inguinal Hernia Market Overview
The Inguinal Hernia Market was valued at around USD 3.2 billion in 2024 and is expected to reach approximately USD 4.8 billion by 2034, growing at a CAGR of about 4.1%. Market growth is driven by rising hernia incidence among older adults, increased adoption of minimally invasive surgery, and advancements in mesh products and fixation devices.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71144
Key Market Drivers
• Increasing…
Liposuction Surgery Devices Market is projected to reach USD 5.76 billion by 203 …
The global Liposuction Surgery Devices Market was valued at USD 2.84 billion in 2024 and is projected to reach USD 5.76 billion by 2034, growing at a CAGR of 7.3% during 2025-2034. Growth is driven by rising demand for body contouring procedures, increasing prevalence of obesity and body-image awareness, expanding cosmetic surgery acceptance, technological innovation in energy-based liposuction platforms, and growth in medical tourism.
Download Full PDF Sample Copy of Market…
Gluten Sensitivity Market was valued at around USD 1.2 billion in 2024 and is pr …
Gluten Sensitivity Market Overview
The Gluten Sensitivity Market was valued at around USD 1.2 billion in 2024 and is projected to reach approximately USD 2.1 billion by 2034, at a CAGR of about 5.6%. Growth is driven by the rising prevalence of non-celiac gluten sensitivity (NCGS), expanding awareness of gluten-related disorders, and increasing adoption of gluten-free food products and diagnostics.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71142
Key Market Drivers
• Increasing…
More Releases for NASH
The Growing Demand For NASH Treatment Amid Obesity Epidemic: A Key Catalyst Acce …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Non-Alcoholic Steatohepatitis (NASH) Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for non-alcoholic steatohepatitis (NASH) has seen a considerable expansion in the past few years. Its value is expected to rise from $4.5 billion in 2024 to $6.06 billion in 2025, marking…
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
NASH Market Insight and Landscape report
Report Snapshot:
NASH is one of the furthermost causes of liver disease worldwide and will probably emerge as the leading cause of end-stage liver disease in the coming years, with the disease affecting both adults and children. The epidemiology and demographic characteristics of NASH vary across different country level. Furthermore, individuals with NAFLD have a high frequency of metabolic comorbidities and could place a growing strain on health-care systems from their…
Nash releases debut EP 'She Don't Know'
London-based singer/songwriter Nash has released his debut EP She Don’t Know. Recorded at the legendary RAK Studios, She Don’t Know has the feel of 60s rock but with a modern twist, leaving the listener hooked throughout and wanting to come back for another listen. She Don’t Know’s leading single CK is an infectious number which is sure to be a hit for 2017.
Listening to the Beatles and Jack White growing…
Nash Technologies at GITEX/GULFCOMMS 2010
Harvey Nash subsidiary presents expert services to telecom operators in the Middle East, Africa and South Asia region
Nürnberg/Germany, 10th September 2010 – For the first time Nash Technologies will be present at GITEX/GULFCOMMS, the largest international trade event for mobile, fixed, IP and satellite communications for the Middle East, Africa and South Asia region, in Dubai from 17th to 21st October 2010 offering its telecom expert services. Nash Technologies will…
